Blog
About

7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An update on the long-acting insulin analogue glargine.

      Basic & Clinical Pharmacology & Toxicology

      Randomized Controlled Trials as Topic, Quality of Life, Insulin, Long-Acting, therapeutic use, analogs & derivatives, Insulin, Hypoglycemic Agents, chemically induced, blood, Hypoglycemia, Humans, psychology, drug therapy, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Child, metabolism, Blood Glucose

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long-term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long-acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years. In many countries glargine is widely used. Here we present an update on the clinical information available on glargine with respect to glycaemic control, the risk of hypoglycaemia and quality of life in both type 1 and type 2 diabetes.

          Related collections

          Author and article information

          Journal
          10.1111/j.1742-7843.2006.pto_352.x
          16867163

          Comments

          Comment on this article